Fertility Bristol Limited 10946488 false 2024-04-01 2024-12-31 2024-12-31 The principal activity of the company is the provision of in-vitro fertilisation and related medical services. Digita Accounts Production Advanced 6.30.9574.0 true true true false true 10946488 2024-04-01 2024-12-31 10946488 2024-12-31 10946488 bus:Director2 2024-12-31 10946488 bus:Director4 2024-12-31 10946488 bus:Director5 2024-12-31 10946488 bus:Director6 2024-12-31 10946488 bus:Director8 2024-12-31 10946488 bus:OrdinaryShareClass1 2024-12-31 10946488 bus:Consolidated 2024-12-31 10946488 core:RetainedEarningsAccumulatedLosses 2024-12-31 10946488 core:ShareCapital 2024-12-31 10946488 core:SharePremium 2024-12-31 10946488 core:CurrentFinancialInstruments 2024-12-31 10946488 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 10946488 core:Non-currentFinancialInstruments core:AfterOneYear 2024-12-31 10946488 core:Goodwill 2024-12-31 10946488 core:BetweenOneFiveYears 2024-12-31 10946488 core:MoreThanFiveYears 2024-12-31 10946488 core:WithinOneYear 2024-12-31 10946488 core:FurnitureFittings 2024-12-31 10946488 core:LandBuildings core:ShortLeaseholdAssets 2024-12-31 10946488 core:PlantMachinery 2024-12-31 10946488 core:DeferredTaxation 2024-12-31 10946488 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-12-31 10946488 core:OtherRelatedParties 2024-12-31 10946488 core:ParentEntities 2024-12-31 10946488 bus:FRS102 2024-04-01 2024-12-31 10946488 bus:Audited 2024-04-01 2024-12-31 10946488 bus:FullAccounts 2024-04-01 2024-12-31 10946488 bus:RegisteredOffice 2024-04-01 2024-12-31 10946488 bus:Director1 2024-04-01 2024-12-31 10946488 bus:Director2 2024-04-01 2024-12-31 10946488 bus:Director4 2024-04-01 2024-12-31 10946488 bus:Director5 2024-04-01 2024-12-31 10946488 bus:Director6 2024-04-01 2024-12-31 10946488 bus:Director8 2024-04-01 2024-12-31 10946488 bus:HighestPaidDirector 2024-04-01 2024-12-31 10946488 bus:OrdinaryShareClass1 2024-04-01 2024-12-31 10946488 bus:Consolidated 2024-04-01 2024-12-31 10946488 bus:PrivateLimitedCompanyLtd 2024-04-01 2024-12-31 10946488 1 2024-04-01 2024-12-31 10946488 core:RetainedEarningsAccumulatedLosses 2024-04-01 2024-12-31 10946488 core:ShareCapital 2024-04-01 2024-12-31 10946488 core:SharePremium 2024-04-01 2024-12-31 10946488 core:Goodwill 2024-04-01 2024-12-31 10946488 core:LandBuildingsUnderOperatingLeases 2024-04-01 2024-12-31 10946488 core:FurnitureFittings 2024-04-01 2024-12-31 10946488 core:LandBuildings 2024-04-01 2024-12-31 10946488 core:LandBuildings core:ShortLeaseholdAssets 2024-04-01 2024-12-31 10946488 core:PlantMachinery 2024-04-01 2024-12-31 10946488 core:KeyManagementPersonnel 2024-04-01 2024-12-31 10946488 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-04-01 2024-12-31 10946488 core:OtherRelatedParties 2024-04-01 2024-12-31 10946488 core:OtherRelatedParties core:RenderingOrReceivingServices 2024-04-01 2024-12-31 10946488 core:ParentEntities 2024-04-01 2024-12-31 10946488 core:UKTax 2024-04-01 2024-12-31 10946488 1 2024-04-01 2024-12-31 10946488 countries:EnglandWales 2024-04-01 2024-12-31 10946488 2024-03-31 10946488 core:RetainedEarningsAccumulatedLosses 2024-03-31 10946488 core:ShareCapital 2024-03-31 10946488 core:SharePremium 2024-03-31 10946488 core:Goodwill 2024-03-31 10946488 core:FurnitureFittings 2024-03-31 10946488 core:LandBuildings core:ShortLeaseholdAssets 2024-03-31 10946488 core:PlantMachinery 2024-03-31 10946488 core:DeferredTaxation 2024-03-31 10946488 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-03-31 10946488 core:OtherRelatedParties 2024-03-31 10946488 core:ParentEntities 2024-03-31 10946488 2023-04-01 2024-03-31 10946488 2024-03-31 10946488 bus:OrdinaryShareClass1 2024-03-31 10946488 core:RetainedEarningsAccumulatedLosses 2024-03-31 10946488 core:ShareCapital 2024-03-31 10946488 core:SharePremium 2024-03-31 10946488 core:CurrentFinancialInstruments 2024-03-31 10946488 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 10946488 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 10946488 core:BetweenOneFiveYears 2024-03-31 10946488 core:MoreThanFiveYears 2024-03-31 10946488 core:WithinOneYear 2024-03-31 10946488 core:FurnitureFittings 2024-03-31 10946488 core:LandBuildings core:ShortLeaseholdAssets 2024-03-31 10946488 core:PlantMachinery 2024-03-31 10946488 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-03-31 10946488 core:OtherRelatedParties 2024-03-31 10946488 bus:HighestPaidDirector 2023-04-01 2024-03-31 10946488 1 2023-04-01 2024-03-31 10946488 core:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 10946488 core:ShareCapital 2023-04-01 2024-03-31 10946488 core:SharePremium 2023-04-01 2024-03-31 10946488 core:LandBuildingsUnderOperatingLeases 2023-04-01 2024-03-31 10946488 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2023-04-01 2024-03-31 10946488 core:OtherRelatedParties 2023-04-01 2024-03-31 10946488 core:OtherRelatedParties core:RenderingOrReceivingServices 2023-04-01 2024-03-31 10946488 core:UKTax 2023-04-01 2024-03-31 10946488 2023-03-31 10946488 core:RetainedEarningsAccumulatedLosses 2023-03-31 10946488 core:ShareCapital 2023-03-31 10946488 core:SharePremium 2023-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10946488

Fertility Bristol Limited

Annual Report and Financial Statements

for the period from 1 April 2024 to 31 December 2024

 

Fertility Bristol Limited

Contents

Company Information

1

Strategic Report

2

Directors' Report

3 to 4

Statement of Directors' Responsibilities

5

Independent Auditor's Report

6 to 8

Profit and Loss Account

9

Balance Sheet

10

Statement of Changes in Equity

11

Statement of Cash Flows

12

Notes to the Financial Statements

13 to 28

 

Fertility Bristol Limited

Company Information

Directors

V Akande

G Beal

Y E Hignell

Registered office

Freshford House
Redcliffe Way
Bristol
BS1 6NL

Auditors

ML Audit LLP
Statutory Auditors
Freshford House
Redcliffe Way
Bristol
BS1 6NL

 

Fertility Bristol Limited

Strategic Report for the period from 1 April 2024 to 31 December 2024

The directors present their strategic report for the period from 1 April 2024 to 31 December 2024.

Principal activity

The principal activity of the company is the provision of in-vitro fertilisation and related medical services.

Fair review of the business

The company generated turnover during the nine-month period to 31 December 2024 of £7.6m (Year ended 31 March 2024: £9.3m), and made a pre-tax loss of £409k (Year ended 31 March 2024: pre-tax profit of £2.0m). The performance of the company for the period ended 31 December 2024 was in line with the expectations of the directors. The financial position of the company is considered satisfactory. Over the year, the company continued to invest in its operational capacity and capabilities to grow its market position and deliver high-quality services.

Principal risks and uncertainties

The key business risks and uncertainties affecting the company relate to changes in the economy, competition from national and international practices, and the introduction of new treatments and procedures. The company mitigates these risks through regular market analysis, investment in research and development, and maintaining high standards of patient care to differentiate itself from competitors.

Financial key performance indicators

Given the straightforward nature of the business, the directors are of the opinion that traditional KPI analysis is not necessary for an understanding of the company’s development, performance, or position. Revenue growth, customer satisfaction and clinical outcomes are monitored internally and have remained strong.

Future developments

The company will continue to invest in cutting-edge technology and expand its service offerings to meet growing patient demand and maintain its competitive advantage.

Outlook

The directors remain confident in the company's ability to continue delivering high-quality services and to achieve sustainable growth in the coming years.

Approved and authorised by the Board on 25 April 2025 and signed on its behalf by:
 

.........................................
V Akande
Director

 

Fertility Bristol Limited

Directors' Report for the period from 1 April 2024 to 31 December 2024

The directors present their report and the financial statements for the period from 1 April 2024 to 31 December 2024.

Directors of the company

The directors who held office during the period were as follows:

V Akande

P Wilson (ceased 29 October 2024)

D Shah (appointed 29 October 2024 and ceased 19 December 2024)

D Rees Jones (ceased 29 October 2024)

G Beal (appointed 19 December 2024)

E McVeigh - Director (ceased 29 October 2024)

Y E Hignell (appointed 29 October 2024)

Results and dividends

The results for the year are set out on page 9.

Ordinary dividends of £Nil were paid during the period (Year ended 31 March 2024 - £3,000,000). The directors do not recommend payment of a final dividend (Year ended 31 March 2024 - £nil).

Financial Instruments

The company has procedures to identify risk and protect and manage the company from events that may hinder its financial performance objectives. The objectives aim to ensure sufficient working capital exists and monitor and manage risk.

Price risk, credit risk, liquidity risk and cash flow risk

Price risk – the company is exposed to price risk as a result of its operations, but the risk is minimised by the demand for its high quality fertility services.

Credit risk – The company manages credit risk effectively by requiring payment in advance for treatment. This policy significantly reduces the risk of non-payment and ensures that the company maintains a secure cash flow. Clear terms and conditions are provided to all patients at the outset, further minimising the company's exposure to credit risk. These measures support the company's financial stability and enable it to continue delivering high-quality fertility services.

Liquidity and cash flow risk – the company’s exposure to liquidity risk is minimal as the company
tightly monitors and controls its cash flow. It also retains the ongoing support of the wider group to help manage its cash flow risk.

Disclosure of information to the auditors

Each director has taken steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditors are unaware.

 

Fertility Bristol Limited

Directors' Report for the period from 1 April 2024 to 31 December 2024

Reappointment of auditors

The auditors ML Audit LLP are deemed to be reappointed under section 487(2) of the Companies Act 2006.

Approved by the Board on 25 April 2025 and signed on its behalf by:

V Akande
Director

   
     
 

Fertility Bristol Limited

Statement of Directors' Responsibilities

The directors acknowledge their responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

select suitable accounting policies and apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Fertility Bristol Limited

Independent Auditor's Report to the Members of Fertility Bristol Limited

Opinion

We have audited the financial statements of Fertility Bristol Limited (the 'company') for the period from 1 April 2024 to 31 December 2024, which comprise the Profit and Loss Account, Balance Sheet, Statement of Changes in Equity, Statement of Cash Flows, and Notes to the Financial Statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the company's affairs as at 31 December 2024 and of it's loss for the period then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements were authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

 

Fertility Bristol Limited

Independent Auditor's Report to the Members of Fertility Bristol Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the Strategic Report and Directors' Report for the financial period for which the financial statements are prepared is consistent with the financial statements; and

the Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

the financial statements are not in agreement with the accounting records and returns; or

certain disclosures of directors' remuneration specified by law are not made; or

we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor Responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud, the audit engagement team:

obtained an understanding of the nature of the industry and sector, including the legal and regulatory framework that the company operates in and how the company is complying with the legal and regulatory framework;

inquired of management, and those charged with governance, about their own identification and assessment of the risks or irregularities, including known and actual, suspected or alleged instances of fraud;

 

Fertility Bristol Limited

Independent Auditor's Report to the Members of Fertility Bristol Limited

discussed matters about non-compliance with laws and regulations and how fraud might occur including assessment of how and where the financial statements may be susceptible to fraud.

However, it is the primary responsibility of management, with the oversight of those charged with governance, to ensure that the entity’s operations are conducted in accordance with the provisions of laws and regulations and for the prevention and detection of fraud.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: http://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

......................................
Tim Lerwill BSc BFP FCA (Senior Statutory Auditor)
For and on behalf of ML Audit LLP, Statutory Auditor
Freshford House
Redcliffe Way
Bristol
BS1 6NL

30 April 2025

 

Fertility Bristol Limited

Profit and Loss Account for the period from 1 April 2024 to 31 December 2024

Note

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Turnover

3

7,636,042

9,330,905

Cost of sales

 

(3,670,235)

(4,388,101)

Gross profit

 

3,965,807

4,942,804

Administrative expenses

 

(4,367,974)

(2,912,717)

Operating (loss)/profit

4

(402,167)

2,030,087

Interest receivable and similar income

5

10,289

12,636

Interest payable and similar expenses

6

(17,106)

(16,235)

   

(6,817)

(3,599)

(Loss)/profit before tax

 

(408,984)

2,026,488

Tax on (loss)/profit

10

(420,011)

(519,690)

(Loss)/profit for the financial period

 

(828,995)

1,506,798

The above results were derived from continuing operations.

The company has no recognised gains or losses for the period other than the results above. As a result, a seperate Statement of Other Comprehensive Income has not been presented.

 

Fertility Bristol Limited

(Registration number: 10946488)
Balance Sheet as at 31 December 2024

Note

31 December
2024
£

31 March
2024
£

Fixed assets

 

Tangible assets

12

2,672,146

2,806,547

Current assets

 

Stocks

13

603,797

583,366

Debtors

14

673,156

1,033,919

Cash at bank and in hand

15

839,363

1,477,163

 

2,116,316

3,094,448

Creditors: Amounts falling due within one year

16

(3,464,370)

(3,658,122)

Net current liabilities

 

(1,348,054)

(563,674)

Total assets less current liabilities

 

1,324,092

2,242,873

Creditors: Amounts falling due after more than one year

16

(76,019)

(165,805)

Provisions for liabilities

17

(407,634)

(407,634)

Net assets

 

840,439

1,669,434

Capital and reserves

 

Called up share capital

215

215

Share premium reserve

20

104,676

104,676

Retained earnings

20

735,548

1,564,543

Shareholders' funds

 

840,439

1,669,434

Approved and authorised by the Board on 25 April 2025 and signed on its behalf by:
 

V Akande
Director

   
     
 

Fertility Bristol Limited

Statement of Changes in Equity for the period from 1 April 2024 to 31 December 2024

Share capital
£

Share premium
£

Retained earnings
£

Total
£

At 1 April 2024

215

104,676

1,564,543

1,669,434

Loss for the period

-

-

(828,995)

(828,995)

At 31 December 2024

215

104,676

735,548

840,439

Share capital
£

Share premium
£

Retained earnings
£

Total
£

At 1 April 2023

215

104,676

3,057,745

3,162,636

Profit for the period

-

-

1,506,798

1,506,798

Dividends

-

-

(3,000,000)

(3,000,000)

At 31 March 2024

215

104,676

1,564,543

1,669,434

 

Fertility Bristol Limited

Statement of Cash Flows for the period from 1 April 2024 to 31 December 2024

Note

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Cash flows from operating activities

(Loss)/profit for the period

 

(828,995)

1,506,798

Adjustments to cash flows from non-cash items

 

Depreciation and amortisation

4

194,996

246,661

Profit on disposal of tangible assets

-

(3,051)

Finance income

5

(10,289)

(12,636)

Finance costs

6

17,106

16,235

Income tax expense

10

420,011

519,690

 

(207,171)

2,273,697

Working capital adjustments

 

Increase in stocks

13

(20,431)

(357,203)

Decrease/(increase) in trade and other debtors

14

360,764

(407,725)

(Decrease)/increase in trade and other creditors

16

(926,823)

1,210,674

Cash (used in)/generated from operations

 

(793,661)

2,719,443

Income taxes paid

10

(146,275)

(189,758)

Net cash flow from operating activities

 

(939,936)

2,529,685

Cash flows from investing activities

 

Interest received

5

10,289

12,636

Acquisitions of tangible assets

12

(60,595)

(134,081)

Proceeds from sale of tangible assets

12

-

35,534

Net cash flows from investing activities

 

(50,306)

(85,911)

Cash flows from financing activities

 

Interest paid

 

(15,904)

(16,235)

Amounts financed by parent company

 

450,000

-

Payments to finance lease creditors

 

(81,654)

(151,893)

Dividends paid

22

-

(3,000,000)

Net cash flows from financing activities

 

352,442

(3,168,128)

Net decrease in cash and cash equivalents

 

(637,800)

(724,354)

Cash and cash equivalents at 1 April

 

1,477,163

2,201,517

Cash and cash equivalents at 31 December/31 March

 

839,363

1,477,163

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Freshford House
Redcliffe Way
Bristol
BS1 6NL

These financial statements were authorised for issue by the Board on 25 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland and the Companies Act 2006'.

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the company, and rounded to the nearest £.

Going concern

The directors have reviewed the company's supply chains, key customers, capital resources and continues to operate within its budgets and forecasts following the year end.

The company made a loss before tax of £408,984 (Year ended 31 March 2024 - profit before tax of £2,026,488) and had a bank balance of £839,363 (31 March 2024 - £1,477,163) at the year ended 31 December 2024.

The directors are confident that the company has sufficient resources and cashflow generated from activity, and the intention of the group and ultimate parent company is to continue operational existence for a period of at least twelve months from the date of signing this report. A formal letter of support has been provided by the parent company in this respect.

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

Key accounting estimates and significant judgements

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision only affects that period, or in the period of the revision and future periods if the revision affects both current and future periods.

During the period, management have made estimates for deferred income of £824,167 (31 March 2024 - £782,508). The basis for these estimates in relation to fertility treatments invoiced upfront are formed from reviewing the stage of treatment at the balance sheet date, which is estimated based on certain treatment milestones being reached.

In determining the closing stock valuation at 31 December 2024 of £603,797 (31 March 2024 - £583,366), management makes significant judgements in the allocation of individual cost elements that comprise the closing finished goods value. These judgements involve estimating attributable material costs, labour costs and overheads.

Revenue recognition

Turnover is derived from the company’s principal activity undertaken in the United Kingdom. Turnover represents the invoiced value of services provided to customers for fertility treatment, including cycles, medication and other associated services, less amounts deferred within creditors.

Turnover is recognised where and to the extent that the company is entitled to it under the terms of its contracts with customers. Drugs are recognised at the point of invoice as that is when they are dispensed to the patient. Invoices raised in advance of fertility treatments are recognised within deferred income and are released to the profit & loss account on a systematic basis in line with when the value of the services invoiced are provided to the customer. Where a contract with a customer includes cryostorage, this is recognised in deferred income at the point of freezing and released to the profit and loss on a straight-line basis.

Prices for treatment are agreed with the customer in advance of any treatment taking place. Contracts with customers do not allow for refunds once services are performed. If a patient is entitled to a refund on services not yet performed, this is recognised when there is an agreement to issue the refund.

Finance income and costs policy

Interest income and expenses are recognised using the effective interest rate method.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Short leasehold land and buildings

6.67% straight line and 20% straight line

Furniture, fittings and equipment

20% straight line and 33% straight line

Plant and machinery

10% straight line

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

50% straight line

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell within the financial statements. The value of stock is determined by attributing purchase costs, costs of conversion, and other attributable overheads incurred in bringing stock to its present location and condition. When considering attributable costs incurred, these consist primarily of labour and other personnel costs incurred when providing the service.

At each reporting date, stocks are assessed for impairment, with any associated impairment loss being recognised immediately in the profit or loss.

Creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Provisions

Provisions are recognised when the company has an obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the relative risks and uncertainties.

Increases in provisions are generally charged as an expense to the profit or loss.

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the
risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the
lease and the present value of the minimum lease payments. These assets are depreciated on a
straight-line basis over the shorter of the useful life of the asset and the lease term. The
corresponding liability to the lessor is included in the Balance Sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the profit and loss and reduction of the
lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the
liability.

Rentals paid under operating leases are charged to the profit and loss on a straight-line basis over the term of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

3

Turnover

The analysis of the company's turnover for the period from continuing operations is as follows:

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Rendering of services

7,635,192

9,328,670

Other revenue

850

2,235

7,636,042

9,330,905

All revenue is generated from sales in the United Kingdom.

4

Operating (loss)/profit

Arrived at after charging/(crediting):

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Depreciation expense

194,996

246,661

Foreign exchange losses

1,170

1,001

Operating lease expense - property

223,420

293,568

Profit on disposal of property, plant and equipment

-

(3,051)

5

Other interest receivable and similar income

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Interest income on bank deposits

10,289

12,636

6

Interest payable and similar expenses

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Interest on obligations under finance leases and hire purchase contracts

15,904

16,235

Interest on group borrowings

1,202

-

17,106

16,235

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

7

Staff costs

The aggregate payroll costs (including directors' remuneration) were as follows:

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Wages and salaries

3,648,898

2,897,032

Social security costs

440,504

305,655

Pension costs, defined contribution scheme

143,896

166,930

Other employee expense

4,076

14,002

4,237,374

3,383,619

The average number of persons employed by the company (including directors) during the period, analysed by category, was as follows:

Period ended
31 December
2024
No.

Year ended
31 March
2024
No.

Administration and support

25

26

Medical

59

58

Directors

4

4

88

88

8

Directors' remuneration

The directors' remuneration for the period was as follows:

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Remuneration

1,657,057

415,416

Contributions paid to money purchase schemes

9,281

8,344

1,666,338

423,760

In respect of the highest paid director:

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Remuneration

1,486,432

164,100

Company contributions to money purchase pension schemes

5,186

-

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

During the period the number of directors who were receiving benefits and share incentives was as follows:

Period ended
31 December
2024
No.

Year ended
31 March
2024
No.

Accruing benefits under money purchase pension scheme

2

2

The directors are considered to be the key management personnel (KMP) of the Company.

9

Auditors' remuneration

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Audit of the financial statements

27,600

24,000


 

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

10

Taxation

Tax charged in the income statement:

Period ended
31 December
2024
£

Year ended
31 March
2024
£

Current taxation

UK corporation tax

420,011

448,297

Deferred taxation

Arising from origination and reversal of timing differences

-

71,393

Tax expense in the income statement

420,011

519,690

The tax on (loss)/profit before tax for the period is higher than the standard rate of corporation tax in the UK (Year ended 31 March 2024 - higher than the standard rate of corporation tax in the UK) of 25% (Year ended 31 March 2024 - 25%).

The differences are reconciled below:

Period ended
31 December
2024
£

Year ended
31 March
2024
£

(Loss)/profit before tax

(408,984)

2,026,488

Corporation tax at standard rate

(102,246)

506,622

Decrease in UK and foreign current tax from adjustment for prior periods

-

(148)

Effect of expense not deductible in determining taxable profit (tax loss)

474,889

1,770

Deferred tax expense from unrecognised temporary difference from a prior period

47,368

11,446

Total tax charge

420,011

519,690

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

11

Intangible assets

Goodwill
 £

Total
£

Cost or valuation

At 1 April 2024

129,928

129,928

At 31 December 2024

129,928

129,928

Amortisation

At 1 April 2024

129,928

129,928

At 31 December 2024

129,928

129,928

Carrying amount

At 31 December 2024

-

-

12

Tangible assets

Short leasehold land and buildings
 £

Furniture, fittings and equipment
 £

Plant and machinery
 £

Total
£

Cost or valuation

At 1 April 2024

2,680,684

9,396

1,188,184

3,878,264

Additions

31,332

3,954

25,309

60,595

At 31 December 2024

2,712,016

13,350

1,213,493

3,938,859

Depreciation

At 1 April 2024

428,398

6,857

636,462

1,071,717

Charge for the period

138,528

817

55,651

194,996

At 31 December 2024

566,926

7,674

692,113

1,266,713

Carrying amount

At 31 December 2024

2,145,090

5,676

521,380

2,672,146

At 31 March 2024

2,252,286

2,539

551,722

2,806,547

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

Assets held under finance leases and hire purchase contracts

The net carrying amount of tangible assets includes the following amounts in respect of assets held under finance leases and hire purchase contracts:

31 December
2024
£

31 March
2024
£

Plant and machinery

321,603

353,666

   

13

Stocks

31 December
2024
£

31 March
2024
£

Finished goods

603,797

583,366

14

Debtors

Current

31 December
2024
£

31 March
2024
£

Trade debtors

385,460

589,506

Prepayments

287,696

444,413

 

673,156

1,033,919

15

Cash and cash equivalents

31 December
2024
£

31 March
2024
£

Cash at bank

827,191

346,950

Short-term deposits

12,172

1,130,213

839,363

1,477,163

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

16

Creditors

Note

31 December
2024
£

31 March
2024
£

Due within one year

 

Trade creditors

 

235,410

556,603

Amounts due to related parties

23

451,202

600,000

Social security and other taxes

 

71,781

88,190

Outstanding defined contribution pension costs

 

-

349

Accruals and deferred income

 

2,000,494

1,989,366

Corporation tax liability

10

591,572

317,836

Current finance lease liabilities

 

113,911

105,778

 

3,464,370

3,658,122

Due after one year

 

Non-current finance lease liabilities

 

76,019

165,805

17

Provisions for liabilities

Deferred tax
£

Total
£

At 1 April 2024

407,634

407,634

At 31 December 2024

407,634

407,634

18

Pension and other schemes

Defined contribution pension scheme

The company operates a defined contribution pension scheme. The pension cost charge for the period represents contributions payable by the company to the scheme and amounted to £143,896 (Year ended 31 March 2024 - £166,930).

Contributions totalling £Nil (31 March 2024 - £349) were payable to the scheme at the end of the period and are included in creditors.

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

19

Share capital

Allotted, called up and fully paid shares

31 December
2024

31 March
2024

No.

£

No.

£

Ordinary A share capital of £0.01 each

21,586

215

21,586

215

       

Rights, preferences and restrictions

Ordinary shares have the following rights, preferences and restrictions:
Ordinary shares carry one voting right per share and the right to dividends.

20

Reserves

Share capital

This reserve reflects the nominal value of the share capital issued by the Company.

Share premium

This reserve reflects the amount above the nominal value received for shares sold, less transaction costs.

Profit and loss account

This reserve reflects the accumulated profits and losses of the Company, net of distributions to owners.

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

21

Obligations under leases and hire purchase contracts

Finance leases

The total of future minimum lease payments is as follows:

31 December
2024
£

31 March
2024
£

Not later than one year

113,911

105,778

Later than one year and not later than five years

76,019

165,805

189,930

271,583

Operating leases

The total of future minimum lease payments is as follows:

31 December
2024
£

31 March
2024
£

Not later than one year

334,445

334,445

Later than one year and not later than five years

1,337,782

1,337,782

Later than five years

2,201,766

2,452,600

3,873,993

4,124,827

22

Dividends

31 December
2024

31 March
2024

£

£

Interim dividend of £Nil (Year ended 31 March 2024 - £138.98) per ordinary share

-

3,000,000

 

 
 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

23

Related party transactions

Key management personnel

Key management personnel comprises directors of the company.

Summary of transactions with other related parties

Other related parties comprise shareholders of the company and other companies controlled by directors of Fertility Bristol Limited.
 

Expenditure with and payables to related parties

Period ended 31 December 2024

Other related parties
£

Rendering of services

49,905

Year ended 31 March 2024

Other related parties
£

Rendering of services

62,040

The company paid the above amounts to a company controlled by one of the directors for the provision of medical services. Included within trade creditors at the period end is £4,620 (Year ended 31 March 2024 - £6,600) owed to the company.
 

Loans from related parties

31 December 2024

Parent
£

Key management
£

Other related parties
£

Total
£

At start of period

-

545,910

54,090

600,000

Advanced

450,000

-

-

450,000

Repaid

-

(545,910)

(54,090)

(600,000)

Interest transactions

1,202

-

-

1,202

At end of period

451,202

-

-

451,202

31 March 2024

Key management
£

Other related parties
£

Total
£

Advanced

545,910

54,090

600,000

At end of period

545,910

54,090

600,000

Terms of loans from related parties

Amounts owed to parent companies are charged at 2.8% plus SONIA interest rates and are repayable within 12 months.
 Amounts owed to key management are interest free and repayable on demand.
 Amounts owed to other related parties are interest free and repayable on demand.

 

Fertility Bristol Limited

Notes to the Financial Statements for the period from 1 April 2024 to 31 December 2024

24

Parent and ultimate parent undertaking

The company's immediate parent is FB Topco Limited, incorporated in England and Wales.

 The ultimate parent is FutureLife a.s., incorporated in the Czech Republic.
 
The parent of the largest group in which these financial statements are consolidated is SynBiol, a.s., incorporated in the Czech Republic. The registered office address of the company is Pyšelská 2327/2, 149 00 Prague 11-Chodov, the Czech Republic.

The parent of the smallest group in which these financial statements are consolidated is Futurelife (UK) Bidco Limited, incorporated in England and Wales. The registered office address of the company is 16 St John St, Barbican, London, United Kingdom, EC1M 4NT.